QDII funds deliver impressive "report card," optimistic about the future of innovative medicine and technology direction.

Since 2025, QDII funds have delivered an impressive "report card", with an average net value increase of 27.9%. Among them, several funds heavily invested in Hong Kong innovative pharmaceuticals have occupied the top spots on the rankings. Several fund managers stated in the latest disclosure of the fund's fourth quarter report for 2025 that innovative pharmaceuticals and technology are still their preferred investment directions for the future. Data from Choice shows that as of January 21 this year, QDII funds have seen an average net value increase of 27.9% since last year. Among them, the Huatai Bairui Hong Kong Advantage Selective Hybrid A and the Huatai Pacific Semi-Conductor ETF have seen net value increases of 127.55% and 102.91% respectively during this period. Additionally, the E Fund Global Growth Selective Hybrid A, the GF Fund Global Medicine and Biotechnology Stock Initiation A, the Industrial Bank New Economy Hybrid Renminbi A, the GF Fund CSI Hong Kong Innovative Pharmaceuticals, and the E Fund Global Pharmaceutical Industry Hybrid A funds have all seen net value increases of over 80%.